Sionna Therapeutics, Inc. (NASDAQ:SION) Stock Has Average Price Target of $42.33 According to Analysts

Shares of Sionna Therapeutics, Inc. (NASDAQ:SION) have been assigned a consensus rating of “Hold” from the thirteen brokerages that are currently covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, eleven have assigned a hold rating and one has given a buy rating to the company. The average 12-month price objective among analysts that have updated their coverage on the stock in the last year is $42.33.

A number of analysts have weighed in on SION shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Sionna Therapeutics in a research note on Wednesday, August 5th. Guggenheim lowered shares of Sionna Therapeutics from a “buy” rating to a “neutral” rating in a research note on Monday, August 10th. Lifesci Capital downgraded shares of Sionna Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Monday, August 10th. Royal Bank Of Canada upgraded Sionna Therapeutics from an “underperform” rating to a “sector perform” rating and set a $5.00 target price on the stock in a research note on Monday, August 10th. Finally, Citizens Jmp cut Sionna Therapeutics from an “outperform” rating to a “market perform” rating in a research note on Monday, August 10th.

Insider Transactions at Sionna Therapeutics

In other Sionna Therapeutics news, Director Ra Capital Management, L.P. sold 3,448,811 shares of the firm’s stock in a transaction that occurred on Thursday, September 17th. The stock was sold at an average price of $6.33, for a total value of $21,830,973.63. Following the sale, the director directly owned 3,448,812 shares of the company’s stock, valued at approximately $21,830,979.96. This trade represents a 50.00% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 5.10% of the company’s stock.

Hedge Funds Weigh In On Sionna Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in SION. State of Wyoming acquired a new position in shares of Sionna Therapeutics during the 2nd quarter worth $35,000. Mitsubishi UFJ Asset Management Co. Ltd. acquired a new stake in shares of Sionna Therapeutics in the second quarter valued at about $44,000. Quantbot Technologies LP purchased a new stake in Sionna Therapeutics during the second quarter worth about $80,000. Strs Ohio purchased a new stake in Sionna Therapeutics during the first quarter worth about $116,000. Finally, AXQ Capital LP purchased a new stake in Sionna Therapeutics during the second quarter worth about $202,000.

Sionna Therapeutics Price Performance

NASDAQ:SION opened at $4.69 on Thursday. The company has a market cap of $212.03 million, a price-to-earnings ratio of -2.15 and a beta of 1.00. Sionna Therapeutics has a 1 year low of $4.01 and a 1 year high of $54.97. The stock’s 50 day simple moving average is $9.49 and its two-hundred day simple moving average is $30.05.

Sionna Therapeutics (NASDAQ:SION) last posted its earnings results on Thursday, August 6th. The company reported ($0.66) EPS for the quarter, missing analysts’ consensus estimates of ($0.64) by ($0.02). As a group, analysts anticipate that Sionna Therapeutics will post -2.54 EPS for the current year.

About Sionna Therapeutics

Sionna Therapeutics, Inc (NASDAQ:SION) is a clinical-stage biopharmaceutical company focused on developing treatments for cystic fibrosis (CF), a genetic disorder caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. The company is developing small-molecule therapies intended to address the underlying cause of CF by improving the production, processing, stability and function of defective CFTR proteins.

Sionna’s research platform is centered on CFTR modulators, including compounds designed to stabilize the CFTR protein’s nucleotide-binding domain 1 (NBD1).